{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-012263","form_type":"8-K","ticker":"HIND","cik":"0001427570","company_name":"Vyome Holdings, Inc","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.025456+00:00","generated_at":"2026-05-31T09:17:28.322411+00:00","sec_items":["2.02","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ReShape Lifesciences enters merger with Vyome Therapeutics, sells assets to Biorad for $5.16M","bullets":["Q2 revenue $2.0M (-12.8% YoY); six-month revenue $3.9M (-13.9% YoY); gross margin improved to 57.7%.","Operating expenses down 45.4% in first half; sales & marketing fell 69.2% in Q2 to $0.7M.","Cash and restricted cash $1.2M as of June 30, with net working capital $2.9M.","Merger with Vyome: all-stock deal; ReShape stockholders to own ~11.1% of combined company.","Asset sale to Biorad Medisys for $5.16M cash; assets include Lap-Band and Obalon systems."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-012263","json":"https://secwatch.observer/filing/0001558370-24-012263.json","markdown":"https://secwatch.observer/filing/0001558370-24-012263.md","text":"https://secwatch.observer/filing/0001558370-24-012263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427570/000155837024012263/0001558370-24-012263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427570/000155837024012263/rsls-20240814x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:17:28.322411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}